PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
40.52%
Revenue growth above 1.5x CSIQ's 1.69%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
-124.82%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-481.19%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2818.90%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-578.55%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-586.21%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-586.21%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.17%
Share count expansion well above CSIQ's 0.05%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.17%
Slight or no buyback while CSIQ is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
478.71%
OCF growth of 478.71% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
293.13%
FCF growth of 293.13% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
554.41%
10Y revenue/share CAGR at 50-75% of CSIQ's 894.94%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
28.41%
5Y revenue/share CAGR above 1.5x CSIQ's 5.26%. David Dodd would look for consistent product or market expansions fueling outperformance.
40.91%
3Y revenue/share CAGR above 1.5x CSIQ's 12.40%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
643.25%
10Y OCF/share CAGR above 1.5x CSIQ's 100.00%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
156.27%
Positive OCF/share growth while CSIQ is negative. John Neff might see a comparative advantage in operational cash viability.
1197.14%
Positive 3Y OCF/share CAGR while CSIQ is negative. John Neff might see a big short-term edge in operational efficiency.
-1257.38%
Negative 10Y net income/share CAGR while CSIQ is at 5.29%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-133.75%
Negative 5Y net income/share CAGR while CSIQ is 83.39%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-1180.57%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-1.90%
Negative equity/share CAGR over 10 years while CSIQ stands at 184.25%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-44.19%
Negative 5Y equity/share growth while CSIQ is at 41.75%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-20.78%
Negative 3Y equity/share growth while CSIQ is at 97.88%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.07%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-10.16%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-10.39%
Negative asset growth while CSIQ invests at 3.46%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-16.78%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-28.73%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-15.25%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-16.93%
We cut SG&A while CSIQ invests at 23.24%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.